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A B S T R A C T
Berberine (BBR) is a renowned natural compound that exhibits potent neuroprotective activities. However, the
cellular and molecular mechanisms are still unclear. Hormesis is an adaptive mechanism generally activated by
mild oxidative stress to protect the cells from further damage. Many phytochemicals have been shown to induce
hormesis. This study aims to investigate whether the neuroprotective activity of BBR is mediated by hormesis
and the related signaling pathways in 6-OHDA-induced PC12 cells and zebraﬁsh neurotoxic models. Our results
demonstrated that BBR induced a typical hormetic response in PC12 cells, i.e. low dose BBR signiﬁcantly
increased the cell viability, while high dose BBR inhibited the cell viability. Moreover, low dose BBR protected
the PC12 cells from 6-OHDA-induced cytotoxicity and apoptosis, whereas relatively high dose BBR did not show
neuroprotective activity. The hormetic and neuroprotective eﬀects of BBR were conﬁrmed to be mediated by up-
regulated PI3K/AKT/Bcl-2 cell survival and Nrf2/HO-1 antioxidative signaling pathways. In addition, low dose
BBR markedly mitigated the 6-OHDA-induced dopaminergic neuron loss and behavior movement deﬁciency in
zebraﬁsh, while high dose BBR only slightly exhibited neuroprotective activities. These results strongly
suggested that the neuroprotection of BBR were attributable to the hormetic mechanisms via activating cell
survival and antioxidative signaling pathways.
1. Introduction
Hormesis is deﬁned as a biphasic dose-response phenomenon that
is characterized by a low-dose beneﬁcial or stimulatory response and a
high-dose toxic or inhibitory response, which has been observed in a
broad range of biological and physiological systems [1–3]. According to
the principles of hormesis, exposure to low concentrations of drugs,
toxins or natural substances may protect against damage from a
subsequent stressor, while at higher dose the toxic eﬀect prevails
[1,4]. Nowadays, hormesis becomes an essential concept to the
biomedical sciences due to its important implications in therapeutics,
in the clinical trial, in drug discovery and risk assessment for
chemicals, radiation and pharmaceutical agents [2,5]. Hormesis has
the potential to improve the quality of life during the normal lifespan,
such as memory enhancement, bone strengthening, anxiety reduction,
and protection against agonists inducing neuronal diseases [4,6].
Recently, the hormesis concept has been receiving increasing attention
in the ﬁeld of neuroscience, including the areas of neuroprotection, and
drugs for Parkinson's disease (PD), Alzheimer's disease (AD),
Huntington's disease (HD), as well as in the areas of behavioral
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pharmacology [1,3,4].
A diverse range of chemicals (phytochemicals, endogenous ago-
nists, synthetic drugs and neurotoxins) have been reported to display a
hormetic responses in neuronal models [7,8]. Interestingly, some anti-
AD drugs exhibit hormetic responses in improving memory [9]. In fact,
neuroprotective agents seem to generally express their neuroprotective
properties in a manner consistent with the hormetic response [7,10]. In
addition, various phytochemicals in moderate amounts exert neuro-
protective eﬀects by enhancing neural cell viability and activating
signaling pathways involving cell survival, anti-apoptosis and anti-
oxidation defense [11,12]. However, substantial evidences are required
to extensively elucidate the biomedical signiﬁcance and the underlying
mechanisms of hormesis.
Berberine (BBR), an isoquinoline alkaloid with PI3K-activating
activity, occurs as an active constituent in the root, rhizome and stem
bark of numerous medicinal plants with abundant pharmacological
activities, including antioxidant, anticancer, anti-inﬂammation, anti-
depressant, neuroprotection, hepatoprotection, cerebroprotection, car-
dioprotection, nephroprotection, etc. [13]. In recent years, BBR has
been demonstrated its beneﬁcial eﬀect in neurodegenerative and
neuropsychiatric disorders because of its dual antioxidant and anti-
apoptotic activities [14–16].
6-hydroxydopamine (6-OHDA) is widely used as a neurotoxin to
generate experimental cell and animal models of PD [17]. PC12 cell
line, derived from pheochromocytoma of rat adrenal medulla, has an
embryonic origin from the neural crest and thus shows a variety of
neuronal properties, including neurotransmitter release, neurite
growth, response to nerve growth factor, etc. PC12 cell line has been
widely used as a cellular model of neuronal development and neuro-
logical diseases [18]. Zebraﬁsh is a well-established model in studies on
development and drug discovery for neurological disorders. The high-
fecundity and short generation time of zebraﬁsh allow fast screening
large numbers of drug candidates at low cost and the transparency of
the zebraﬁsh allows visualization of biochemical, physiological and
anatomic states in a living vertebrate organism [19]. Moreover, the
zebraﬁsh shares genetic, physiologic and anatomic homology to higher
order vertebrates, especially, the structure and function of the zebraﬁsh
brain are very similar to those of other vertebrates, and 6-OHDA is
known to induce dopaminergic (DA) neuronal death and Parkinson's
pattern in zebraﬁsh.
Previous studies found that BBR exert neuroprotective eﬀects
against 6-OHDA and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
induced neurotoxicity in PC12 cells and a rat model of neurodegen-
erative diseases [20,21], whereas the underlying cellular and molecular
mechanisms are still unclear. We have recently reported that BBR
could enhance the survival of cancer cells at low doses via a hormetic
mechanisms [22]. We speculate that the neuroprotective activity of
BBR might be attributable to the hormetic mechanisms activated by
relatively low dose BBR. To address this question, we characterized the
hormetic and neuroprotective activities of BBR in 6-OHDA-induced
neurotoxicity in PC12 cells and zebraﬁsh, and investigated the involved
signaling pathways in the current study.
2. Materials and methods
2.1. Chemicals and reagents
BBR with the purity greater than 99%, 6-OHDA, dimethyl sulfoxide
(DMSO), nomifensine (Nom), and thiazolyl blue tetrazolium bromide
(MTT) were purchased from Sigma-Aldrich Co (St. Louis, MO, USA). F-
12K medium, phosphate buﬀered saline (PBS), penicillin-streptomycin
(PS) were purchased from Gibco (Maryland, USA). Fetal bovine serum
(FBS) and horse serum (HS) were obtained from Invitrogen (Carlsbad,
CA, USA). Antibodies against phosphor-phosphoinositide 3-kinase (p-
PI3K), PI3K, Bcl-2, phosphor-protein kinase B (p-AKT), AKT, nuclear
factor-E2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1) and
GAPDH, and secondary antibodies were obtained from Cell Signaling
Technology (Danvers, MA, USA) or Proteintech (Chicago, IL, USA).
Secondary antibody ﬂuorescein isothiocyanate (FITC) was obtained
from Abcam Inc (Cambridge, MA, USA). Hoechst 33342 staining kit,
LY294002, Annexin V-FITC/propidium iodide (PI) apoptosis detection
kit, caspase-3 activity assay kit, cell cycle and apoptosis analysis kit,
and the terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) cell apoptosis detection kit were obtained from
Beyotime Institute of Biotechnology (Nanjing, Jiangsu, China). Zinc
protoporphyrin IX (ZnPP) was obtained from Enzo Life Sciences
(Farmingdale, NY, USA).
2.2. Cell culture and drug treatments
The PC12 cell line was purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). Cells were maintained in
ATCC-formulated F-12K medium containing 15% (v/v) heat-inacti-
vated HS, 2.5% (v/v) FBS, and 1% (v/v) PS, and incubated in a
humidiﬁed atmosphere of 5% CO2 at 37 °C. For the following in vitro
experiments, the working solutions of BBR were freshly dissolved and
diluted in the basal medium.
2.3. Cell viability assay
Cell viability was measured using MTT method [23]. Brieﬂy, PC12
cells (6 × 103 cells/well) were treated with increasing concentrations of
BBR for 24 h in 96-well plates. To test the neuroprotective eﬀect of low
dose BBR against 6-OHDA-induced cell death, PC12 cells were
pretreated with indicated concentrations of BBR for 24 h prior to the
treatment of 250 µM 6-OHDA for a further 24 h. Then, the treated cells
were incubated in 0.50 mg/mL MTT solution for 4 h at 37 °C. The
supernatants were replaced with DMSO to dissolve the formazan
crystals. The absorbance was determined using a microplate reader
(BioTek, Winooski, VT, USA) with a test wavelength at 570 nm. The
relative viability of treated cells was calculated comparing with OD
value of control group.
2.4. TUNEL
TUNEL method was performed to label 3′-end of fragmented DNA
of the apoptotic PC12 cells. The cells were treated as mentioned in cell
viability assay, and ﬁxed with 4% paraformaldehyde phosphate buﬀer
saline for 45 min at room temperature, rinsed with PBS, and permea-
bilized by 0.1% Triton X-100 for 2 min on ice followed by TUNEL for
60 min at 37 °C in a humidiﬁed atmosphere in the dark. The TUNEL-
positive cells were imaged using the InCell 2000 confocal microscope
(GE Biosciences, Piscataway, NJ, USA). Quantitative analysis of
apoptotic cells using the software modules supplied with the InCell
2000.
2.5. Annexin V-FITC/PI staining
The cells treated as indicated were washed with PBS and resus-
pended in the binding buﬀer containing Annexin V-FITC and PI for
15 min in the dark. Then the cells were detected by ﬂow cytometry
(FCM, FACS Canto™, BD, CA, USA). The percentage of apoptotic cells
was counted using FlowJo software version 7.6.1 (Ashland, OR, USA).
2.6. FACS analysis for sub-G1 DNA determination
DNA fragmentation during apoptosis causes considerable loss of
DNA content, resulting in an obvious sub-G1 peak [24]. For sub-G1
DNA content analysis, the treated cells were harvested and ﬁxed in ice-
cold 70% ethanol at −20 °C overnight, and then stained with PI for
15 min. Cells were maintained in the dark and analyzed by FCM. The
percentage of cells in the sub-G1 phase of the cell cycle was calculated
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using FlowJo software version 7.6.1.
2.7. Measurement of caspase-3 activity
Caspase-3 activity was carried out using the C1116 Caspase-3
Activity Assay kit according to the manufacturer's instructions. In
brief, the treated cells were harvested and washed by ice-cold PBS,
resuspended in lysis buﬀer on ice for 15 min, and centrifuged for
15 min at 16000g. Then the supernatant of each sample was incubated
with Ac-DEVD-рNA/Ac-LEHD-pNA and detecting buﬀer at 37 °C for
120 min. The OD value was measured at 405 nm with a microplate
reader.
2.8. Nrf2 immunoﬂuorescence
The nuclear translocation of Nrf2 was determined by immunostain-
ing as previously described [25]. Brieﬂy, PC12 cells were treated with
BBR (1 µM). Then, the cells were washed with PBS and ﬁxed in 4%
paraformaldehyde, permeabilized with 0.5% Triton X-100, blocked
with 1% BSA and then incubated with anti-Nrf2 antibody. The bound
antibody was detected by FITC-IgG secondary antibody. DAPI was
used for counterstaining of nuclei. The stained cells were washed with
PBS and visualized using the InCell 2000 confocal microscope.
2.9. Western blotting
The collected cells were lysed with RIPA lysis buﬀer containing 1%
phenylmethylsulfonyl ﬂuoride and 1% protease inhibitor cocktail
(Thermo, Rockford, IL, USA). The sample protein concentrations were
determined using a BCA protein assay kit (Thermo, Rockford, IL, USA).
Equivalent amounts of proteins from each group were separated by
SDS-polyacrylamide gel electrophoresis, followed by transferring onto
methanol activated PVDF membranes (Bio-Rad, Philadelphia, PA,
USA). After being blocked with 5% skim milk with PBST buﬀer, the
membranes were probed overnight at 4 °C with the indicated primary
antibodies (1:1000) and incubated with the corresponding secondary
antibodies (1:5000). Protein bands were detected by Bio-Rad
ChemiDoc™ (Hercules, CA, USA).
2.10. Inhibitor Treatment
To clarify the roles of signaling pathways in low dose BBR-induced
hormetic eﬀect in PC12 cells, the cells were pretreated with or without
10 µM ZnPP (HO-1 inhibitor) or 10 µM LY294002 (PI3K/AKT path-
way inhibitor) for 1 h and then treated with 1 µM BBR for 24 h. The
cells were then subjected to the determination of cell viability of PC12
cells by MTT assay and hormesis-related protein levels by Western
blotting. To analyze the roles of signaling pathways in low dose BBR-
triggered neuroprotective eﬀect in PC12 cells, the cells were treated
with BBR (1 µM) for 24 h and then incubated with ZnPP for 1 h; PC12
cells were pre-incubated with LY294002 for 1 h and then treated with
BBR (1 µM) for 24 h. Drug-treated cells were further treated with
250 µM 6-OHDA for 24 h. Then the cells were subjected to the
measurement of cell viability by MTT assay and apoptosis by cas-
pase-3 activity assay, sub-G1 DNA content analysis, and Annexin V-
FITC/PI staining.
2.11. Anti-tyrosine hydroxylase (TH) whole-mount immunostaining
The AB strain of wild-type zebraﬁsh was used in this study and all
animal experiments were conducted following ethical guidelines of
Institute of Chinese Medical Sciences, University of Macau. Zebraﬁsh
maintenance were performed as described previously [26]. Zebraﬁsh
embryos at 1 day post fertilization (dpf) were treated for 2 days with
indicated concentrations of BBR in the presence or in the absence of 6-
OHDA. Then zebraﬁsh larvae were ﬁxed in 4% paraformaldehyde in
PBS for 30 min, rinsed, and stored at −20 °C in 100% MtOH. Whole-
mount immunostaining and semi-quantiﬁcation of TH+ cells were
performed as previously described [26]. Results are expressed as
percentage of area of TH+ cells of that of the untreated normal control
group.
2.12. Locomotion behavioral test of zebraﬁsh
Zebraﬁsh larvae at 3 dpf were co-incubated with 250 µM 6-OHDA
and Nom or BBR at the indicated concentrations for 4 days. Zebraﬁsh
at 7 dpf were transferred into 96-well plate (1 ﬁsh/well). Zebraﬁsh
behavior was analyzed using an automated video tracking system
(Viewpoint, ZebraLab, LifeSciences). The swimming pattern and total
distance traveled of each ﬁsh were recorded for 10 min. The larvae
were allowed to accommodate to the new environment for 30 min
2.13. Statistical analysis
All the data were expressed as means ± SD of three independent
experiments. One-way ANOVA followed with Tukey's multiple compar-
ison are used in the GraphPad Prism statistical software (GraphPad
Software, San Diego, CA, USA). The value of statistical signiﬁcance is
set at P < 0.05.
3. Results
3.1. Low dose BBR induced hormetic eﬀect and attenuated 6-OHDA-
induced cell damage in PC12 cells
To investigate the hormetic eﬀect of BBR, PC12 cells were treated
with BBR at concentrations ranging from 0.1 to 64 µM for 24 h. The
cell viability of BBR was assessed by MTT assay. As shown in Fig. 1A,
BBR at a concentration of 1 µM increased cell viability by 33.3% and
did not show cytotoxicity up to the concentration of 8 µM. In contrast,
treatment with BBR at a concentration of 64 µM signiﬁcantly reduced
cell viability by 47.3%. This biphasic dose-response phenomenon was
in agreement with the typical character of hormesis [27,28].
We hypothesized that the hormetic eﬀect of low dose BBR could
attenuate 6-OHDA-induced cell damage. To test this hypothesis, PC12
cells were treated with 0.12–16 µM BBR for 24 h and then incubated
with or without 250 µM 6-OHDA for a further 24 h. As shown in
Fig. 1B, low dose BBR signiﬁcantly protected PC12 cells from 6-OHDA-
induced cell death. Particularly, 1 µM BBR exhibited the highest
protective activity of 22.0% as compared to 6-OHDA alone. However,
co-treatment of high dose BBR (16 µM) did not show any protective
eﬀect. Next, we determined whether low dose BBR could protect PC12
cells against 6-OHDA-induced apoptosis. The results from TUNEL
staining showed that the apoptotic rates was decreased from 50.9% to
31.7% in the group of 6-OHDA (250 µM) used alone comparing to 6-
OHDA plus BBR (1 µM) (Fig. 1C and D). Meanwhile, our results
revealed that the induction of apoptosis by treatment of 6-OHDA was
further evidenced by increased expression of cleaved caspase-3,
decreased expression of Bcl-2, and increased activity of caspase-3.
Interestingly, addition of low dose BBR signiﬁcantly suppressed the
level of cleaved caspase-3 expression, increased the levels of total
caspase-3 and Bcl-2 expressions, and decreased the activity of caspase-
3 in PC12 cells (Figs. 1E and 4G). These results demonstrated that the
hormetic eﬀect of low dose BBR signiﬁcantly suppressed the in vitro 6-
OHDA-induced neurotoxicity. The degree of suppression was depen-
dent on the concentration of treatment. Our data also provided
important information to discern the biomedical signiﬁcance of horm-
esis.
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Fig. 1. BBR induced hormetic eﬀect in PC12 cells and protective eﬀects against 6-OHDA-induced cell damage. PC12 cells were treated with increasing concentrations of
BBR for 24 h (A), and then incubated with or without 250 µM 6-OHDA for a further 24 h (B). The cell viability was measured using MTT method. (C) PC12 cells were pretreated with
1 µM BBR for 24 h and then treated with or without 250 µM 6-OHDA for 24 h were analyzed for apoptosis using Hoechst 33342 and TUNEL staining, and visualized by InCell Analyzer
2000 (20X objective). Scale bars represent 50 µm. (D) Quantiﬁcation of apoptotic cells (C). PC12 cells were treated with indicated concentrations of BBR for 24 h, 6-OHDA was then
added to the cells for a further 24 h and the protein levels of cleaved caspase-3, caspase-3 and Bcl-2 were detected by Western blot (E). (F) and (G) were densitometric analysis of (E)
from three experiments. Values represent the mean ± SD (n = 3). **P < 0.01, versus control group in (A); *P < 0.05, **P < 0.01 versus 6-OHDA-treated alone groups in (B), (D), (F)
and (G).
C. Zhang et al. Redox Biology 11 (2017) 1–11
4
Fig. 2. Eﬀects of BBR on the expression levels of components of PI3K/AKT/Bcl-2 and Nrf2/HO-1 signaling pathways. PC12 cells were treated with varying
concentrations of BBR for 24 h (A, B), or the cells were treated with 1 µM BBR for diﬀerent time points (C). Levels of total and phosphorylated proteins were determined by Western blot.
(D), (E), (F) and (G) were densitometric analysis of (A), (B) and (C) from three experiments. *P < 0.05 and **P < 0.01, versus control. (H) Nuclear translocation of Nrf2 was detected
using immunoﬂuorescence assay. Analysis was performed by InCell 2000 confocal microscope (60X objective). Blue and green ﬂuorescences indicate localization of nucleus (DAPI) and
Nrf2 respectively. Scale bars represent 20 µm.
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3.2. Low doses of BBR up-regulated PI3K/AKT/Bcl-2 and Nrf2/HO-1
pathways
Since PI3K/AKT/Bcl-2 pathway and Nrf2/HO-1 pathway play
pivotal roles in cell growth/survival [29–31] and adaptive oxidative
response [32–34], we hypothesized that PI3K/AKT/Bcl-2 and Nrf2/
HO-1 signaling pathways were involved in the hormetic eﬀect induced
by low dose BBR. We examined the phosphorylated and total protein
levels of PI3K, AKT, Bcl-2, HO-1 and Nrf2 treated with low dose BBR
in PC12 cells by Western blotting assay. Our data showed that low
doses of BBR upregulated the levels of p-PI3K and p-AKT, and the
expression levels of Bcl-2, HO-1 and Nrf2 proteins in PC12 cells
(Fig. 2A to C). To determine low dose BBR-mediated nuclear translo-
cation of Nrf2, nuclear import of Nrf2 in control and treated cells was
monitored by immunoﬂuorescence. As shown in Fig. 2H, Nrf2 was
mainly located in the cytoplasm of PC12 cells in the control group, and
the ﬂuorescence intensity of the nuclear Nrf2 was more signiﬁcantly
increased after BBR treatment (1 µM), indicating that BBR facilitates
the Nrf2 accumulation in the nucleus. Moreover, LY294002 signiﬁ-
cantly reversed the increased protein levels of Bcl-2, HO-1 and Nrf2
(Fig. 3A). These results indicated that the hormetic eﬀect of low dose
BBR on PC12 cells were through activating PI3K/AKT/Bcl-2 and Nrf2/
HO-1 signaling pathways.
3.3. Inhibition of PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways
attenuated the hormetic and neuroprotective eﬀects of low dose BBR
To further conﬁrm the roles of PI3K/AKT/Bcl-2 cell growth/
survival pathway and Nrf2/HO-1 antioxidant pathway in the hormetic
eﬀect of BBR, we tested whether the pathway inhibitors could aﬀect the
hormetic eﬀect of BBR in PC12 cells. The MTT colorimetric assay
revealed that low dose BBR increased viability of PC12 cells by about
30% (dose of 1 µM), which was consistent with previous result in
Fig. 1A. However, co-treatment of BBR and 10 µM PI3K/AKT pathway
inhibitor LY294002 (Fig. 4A), or 10 µM HO-1 inhibitor ZnPP (Fig. 4B),
partially abolished the viability enhancement by low dose BBR in PC12
cells, indicating that PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways are
involved, at least partially, in the hormetic eﬀect of low dose BBR on
PC12 cells.
We further investigated whether PI3K/AKT/Bcl-2 and Nrf2/HO-1
pathways participate in the neuroprotective eﬀect of BBR at low doses
in PC12 cells. As shown in Fig. 4A and B, the MTT colorimetric assay
revealed that 1 µM BBR displayed about 30% neuroprotective activity
comparing to the group of 6-OHDA alone treatment, which was similar
to the result shown in Fig. 1B. However, addition of LY294002
(Fig. 4A) or ZnPP (Fig. 4B), the neuroprotective eﬀect of BBR at low
doses against 6-OHDA-induced cell death was markedly abolished
comparing to the co-treatment of BBR and 6-OHDA group. We further
assessed whether the neuroprotective eﬀect of low dose BBR against 6-
OHDA-induced apoptosis was aﬀected by these inhibitors in PC12
Fig. 3. The role of PI3K in BBR-induced hormetic eﬀect in PC12 cells. PC12 cells were exposed to 1 µM BBR for 24 h with or without pretreatment of 10 µM LY294002 for 1 h.
(A) The protein levels of HO-1, Nrf2 and Bcl-2 were detected by Western blot. (B), (C) and (D) were densitometric analysis of (A) from three experiments. Values represent the mean
± SD (n = 3). **P < 0.01, compared to BBR-treated alone groups.
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Fig. 4. PI3K and HO-1 inhibitors attenuated BBR-induced hormesis and neuroprotection in PC12 cells. (A) PC12 cells were pre-incubated with or without 10 µM
LY294002 for 1 h and then treated with 1 µM BBR for 24 h; (B) PC12 cells were treated with 1 µM BBR for 24 h and then incubated with or without 10 µM ZnPP for 1 h. BBR and
inhibitor-treated cells were further treated with or without 250 µM 6-OHDA for 24 h. Cell viability was detected by MTT assay (A) and (B). The eﬀect of PI3K inhibitor on the
neuroprotective activity of BBR against 6-OHDA-induced apoptosis was determined using Annexin V/PI staining (C) and subG1 peak analysis (D) by ﬂow cytometry, and also was
evaluated by determination of the activity of caspase-3 by ELISA reader (G and H). (E) and (F) were quantiﬁed results of (C) and (D), respectively. Values represent the mean ± SD
(n = 3). **P < 0.01, compared to BBR-treated alone groups or BBR + 6-OHDA-treated groups in (A) and (B). **P < 0.01 versus BBR + 6-OHDA-treated groups in (E), (F), (G) and (H).
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cells. Results from Annexin V/PI double staining assay (Fig. 4C), sub-
G1 phase detection (Fig. 4D) and caspase-3 activity detection (Fig. 4G
and H) indicated that the apoptotic rates were lower in PC12 cells co-
treated with BBR and 6-OHDA comparing to the groups of 6-OHDA
treatment alone. However, LY294002 and ZnPP attenuated the neu-
roprotective eﬀects of low dose BBR against 6-OHDA-induced apop-
tosis in PC12 cells (Fig. 4C to H). These results demonstrated that
PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways were involved, at least
partially, in the neuroprotective eﬀect of BBR at low doses on PC12
cells.
3.4. Low doses of BBR prevented 6-OHDA-induced dopaminergic
(DA) neuronal loss in in vivo models of PD
To conﬁrm the neuroprotective eﬀect of low dose BBR in vivo, we
evaluated the DA neuron system of zebraﬁsh larvae by immunoﬂuor-
escent staining with a speciﬁc antibody against anti-TH. As shown in
Fig. 5, treatment with 6-OHDA decreased the number of DA neurons
markedly in the diencephalon of zebraﬁsh (indicated by the red
brackets). Low dose BBR (0.3, 0.6 and 1.3 µM) signiﬁcantly alleviated
the loss of DA neurons in a dose-dependent manner, suggesting that
low dose BBR exhibits protective eﬀect against 6-OHDA-induced DA
neuron death in zebraﬁsh. However, high dose of BBR (20 µM) did not
show protective eﬀect against 6-OHDA-induced DA neuron loss.
3.5. Low doses of BBR rescued the deﬁcit of locomotor activity in 6-
OHDA-treated zebraﬁsh
In zebraﬁsh larvae, loss of dopamine stimulation results in deﬁcits
of locomotive behavior. As shown in Fig. 6, treatment with 6-OHDA
markedly altered the swimming behavior and reduced the total
swimming distance of zebraﬁsh larvae (from 200 to 97 mm), whereas
Nom reduced this deﬁcit (172 mm). Under the same conditions, 0.3,
0.6 and 1.3 µM of BBR suppressed 6-OHDA-induced reduction in total
movement distance in a concentration-dependent manner (126, 154
and 183 mm, respectively). However, high dose BBR (20 µM) only
exerted slightly protective eﬀect against 6-OHDA-induced movement
decreases (125 mm).
4. Discussion
In recent years, phytochemicals have been proposed to generally
induce hormetic response in neural system, or so called neurohormesis
[12,35]. Since hormesis is an adaptive response which could lead to
robust cellular protection against further damage in cells or organisms,
we speculate that phytochemicals may generally induce hormetic
response and activation of related cell growth/survival and anti-
oxidation pathways to protect neural cell damage. In the current study,
we investigated whether BBR could induce hormetic response and
neuroprotective eﬀect and their relationship in PC12 cells and zebra-
ﬁsh. We found that BBR induced a typical hormetic eﬀect in PC12 cells,
i.e. low dose BBR increased cell viability while relatively high dose BBR
Fig. 5. The eﬀect of BBR on 6-OHDA-induced dopaminergic (DA) neuron loss in zebraﬁsh. Zebraﬁsh embryos at 1 day post fertilization were exposed to diﬀerent
concentrations of BBR or nomifensine (Nom, used as a positive control), and then treated with or without 250 µM 6-OHDA for 48 h. Then zebraﬁsh larvae were ﬁxed for whole-mount
immunostaining. (A) Representative morphology of DA neurons in the zebraﬁsh brain indicated by immunostaining with antibody against tyrosine hydroxylase (TH). (B) Statistical
analysis of TH+ neuron in each group, 10 ﬁsh/group were used. Values represent the mean ± SD (n = 3). Data is expressed as a percentage of the control group. ###P < 0.01 versus
control (CTL) group, **P < 0.01 versus vehicle (Veh) + 6-OHDA-treated group.
Fig. 6. The eﬀect of BBR on 6-OHDA-induced deﬁcits in the locomotor
behavior of zebraﬁsh. Zebraﬁsh larvae at 3 day post fertilization were exposed to
indicated concentrations of BBR with or without 250 µM 6-OHDA for 4 days. Then larvae
were collected to perform locomotion behavior test using the Viewpoint Zebrabox
system; the total distance traveled in 10 min was calculated. (A) Typical swimming
patterns of control and diﬀerent treatment groups. (B) Statistical analysis of total
distance moved of control and diﬀerent treatment groups, eight ﬁsh larvae per group
were used and experiments were repeated three times. Nom used as a positive control.
###P < 0.01 versus CTL group, **P < 0.01 versus Veh + 6-OHDA-treated group.
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decreased cell viability (Fig. 1A). Meanwhile, low dose BBR markedly
protect PC12 cells from 6-OHDA-induced cytotoxicity and apoptosis,
whereas relatively high dose BBR did not show obvious protective
activity (Figs. 1B-G, 4G and H), indicating that the neuroprotective
eﬀect of BBR is in a hormetic dose response manner. These results are
in line with our previous reports that low dose camptothecin exhibited
hormetic and neuroprotective eﬀects in PC12 cells [22], and low dose
BBR attenuated the anticancer activity of chemotherapeutic drugs in
B16-F10 melanoma cells [36]. Several studies have shown that BBR
can recognize and directly bind speciﬁc DNA sequences by intercala-
tion and form DNA triplexes or G-quadruplexes, thereby triggering
DNA repair process and oxidative stress [37], which could be respon-
sible for the induction of hormetic response by BBR [38]. Our data
strongly suggested that the hormetic eﬀect of BBR may be underlying
its neuroprotective activity in PC12 cells. Furthermore, we tested and
characterized the neuroprotective activity of BBR in 6-OHDA-induced
zebraﬁsh PD model, which is a powerful model for discovery of anti-PD
neuroprotective agents [39,40], since the structure and function of the
zebraﬁsh brain are highly similar to those of other vertebrates [41] and
6-OHDA is generally used to cause DA neuronal death and Parkinson's
pattern in animals [42]. We demonstrated that low dose BBR markedly
attenuated the 6-OHDA-induced DA neuron loss and behavior move-
ment deﬁciency in zebraﬁsh. However, relatively high dose BBR
exerted no or slightly neuroprotective eﬀect, being indicative of a
hormetic dose response (Figs. 5 and 6). These data further conﬁrmed
the role of hormetic response in the neuroprotective eﬀect of low dose
BBR. Evoking nonharmful endoplasmic reticulum stress and protective
autophagy, which were thought to be hormetic mechanisms [43], could
prevent neuronal cell death in animal PD models [1,44]. These were in
accordance with the hypothesis that hormetic mechanisms could be
novel targets for therapeutic intervention in neurodegenerative dis-
orders (NDD) [6,45].
Hormesis is terminologically equivalent to adaptive response [27],
which involves a broad range of stress response proteins and pathways
[46]. Accumulating studies indicated that various phytochemicals
could ameliorate neurological disorders through activating pro-survival
and antioxidant pathways [12,47]. However, diﬀerent stimuli may
overwhelmingly activate one or more hormetic mechanisms in certain
biological systems. In the present study, we found that low dose BBR
treatment markedly increased the levels of p-PI3K and p-AKT, and the
expression level of Bcl-2 (Fig. 2A). Our data also showed that the
induction of Bcl-2 expression by low dose BBR could be attenuated by
PI3K/AKT pathway inhibitor LY294002 (Fig. 3A), and co-treatment of
LY294002 abolished the viability-enhancing eﬀect and protective eﬀect
of BBR against 6-OHDA-induced cytotoxicity (Fig. 4A) and apoptosis
(Fig. 4C, D and G) in PC12 cells. PI3K/AKT pathway is critical for
neuronal survival by promoting cell survival and inhibiting apoptosis,
and is also one of the major signaling pathways participating in
hormesis [48]. AKT, a serine/threonine kinase, is the key mediator of
PI3K-initiated signaling and can promote neuronal survival by upre-
gulating the expression of Bcl-2 through cAMP-response element-
binding protein [49]. Bcl-2 has been recognized for its pro-survival,
antioxidant, antiapoptotic and cytoprotective functions, and plays a
pivotal role in hormetic response [50]. Our results suggest that PI3K/
AKT/Bcl-2 pathway plays a key role in BBR-elicited hormetic response
and protective eﬀect against 6-OHDA-caused apoptosis in PC12 cells.
Previous studies have shown that PI3K/AKT pathway could be
activated in response to oxidative stress [51,52]. We speculate that
the activation of PI3K/AKT/Bcl-2 is attributable to the mild oxidative
stress induced by low dose BBR.
Excessive oxidative stress caused mitochondrial dysfunction has
been proposed to be associated with NDD [53] and brain aging [54].
Therefore, reducing oxidative damage to neuronal cells could be a
promising preventive and therapeutic approach. Increasing evidence
suggests that many phytochemicals can activate pathways that prevent
or reverse oxidative injury [55]. The Nrf2/HO-1 signaling pathway is
crucial for neuroprotection against oxidative stress [32–34] and
involved in the process of hormesis [36,56–58]. Nrf2 is a stress-
responsive transcriptional factor and an important eﬀector protecting
cells from oxidative injury, particularly neurodegenerative diseases.
Under oxidative stress, Nrf2 releases from Keap1 and translocates into
the nucleus and recruits the small Maf (sMaf) protein. The Nrf2-sMaf
heterodimer then binds to the antioxidant response element (ARE) to
promote the expression of many antioxidant enzymes, such as HO-1,
NAD(P)H-quinone oxidoreductase, superoxide dismutase 3, glucuro-
nosyltransferase-1a6 and glutathione S-transferase. These enzymes
exert antioxidant and cytoprotective eﬀects in response to oxidative
stress [59,60]. Among the ARE-regulated phase II detoxifying enzymes
and antioxidants, HO-1 is the major enzyme regulated by Nrf2 since it
has the most strong AREs on its promoter, making it a potent
therapeutic target for neurodegenerative diseases [61]. Numerous
phytochemicals (e.g., curcuminoids, isothiocynates, Z-ligustilide, cate-
chins, indoles, terpenes, diallyl sulﬁdes) have been shown to activate
one or more signaling pathways upstream of Nrf2/HO-1 axis, thus
protecting neurons against oxidative stress [12,47]. In fact, the Nrf2
can be a downstream eﬀector of several signal pathways, including
MAPK, PI3K/AKT and protein kinase C to coordinate mammalian
defense systems against electrophiles and oxidative stresses [62]. In the
present study, low dose BBR signiﬁcantly increased the levels of Nrf2
and HO-1 in PC12 cells (Fig. 2B and C), and promoted Nrf2 nuclear
translocation (Fig. 2H). Inhibition of the Nrf2/HO-1 pathway with
ZnPP (a HO-1 inhibitor) reversed the viability-enhancing (Fig. 4B) and
neuroprotective eﬀects of BBR (Fig. 4B and H) in PC12 cells. These
results demonstrated that Nrf2/HO-1 pathway was also responsible for
the hormetic and neuroprotective eﬀects of BBR. In addition,
LY294002 could reduce the levels of Nrf2 and HO-1 in the presence
of BBR (Fig. 3A), suggesting that low dose BBR protected PC12 cells
against 6-OHDA-induced cytotoxicity through enhancing the activity of
Nrf2/HO-1 triggered by PI3K/AKT signaling pathway. This is in line
with previous reports [47,63].
In summary, we demonstrated that relatively low dose BBR
exhibited strong neuroprotective activity against 6-OHDA-induced
neurotoxicity in PC12 cells and zebraﬁsh through activating hormetic
mechanisms involving up-regulated PI3K/AKT/Bcl-2 cell survival and
Nrf2/HO-1 antioxidant pathways (as depicted in Fig. 7). This study
provides new insight into the mechanisms for the neuroprotective
eﬀect of BBR. BBR has been approved for clinical trials in the
treatment of hyperglycemia and hyperlipidemia [13]. However, the
Fig. 7. A schematic model of upregulated PI3K/AKT/Bcl-2 cell survival pathway and
Nrf2/HO-1 antioxidant pathway by low doses of BBR in PC12 cells.
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preclinical and clinical studies of neuroprotective activities of BBR have
not been documented to date. Our data and others strongly suggest that
BBR is a potential candidate agent for the prevention and treatment of
neurodegenerative diseases. In addition, we presented direct experi-
mental evidences to conﬁrm that induction of hormetic responses in
neuronal cells could not only be a general mechanism for the
neuroprotective activity of many phytochemicals with multiple targets
[11,12], but also a new approach for the management of neurodegen-
erative disorders [6,45].
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